Biotech Company GangaGen raises $1.8mn
Bangalore (and US) based Biotech research company, GangaGen has raised $1.8mn from ATEL ventures.
The funding will be used to develop treatments for antibiotic-resistant bacterial infections like MRSA, a skin infection that plagues hospitals, and pneumonia (via)
Recommended Read: Green Tech Investments in India | The Great Indian Energy Innovation!
About the author - Ashish Sinha is a Startup Mentor/Product Strategy Coach, and the founder/chief editor of pluGGd.in.
He has launched/managed couple of products (consumer as well as enterprise) in US and India, and now consults with startups/small businesses on their product/media strategy. He can be reached at: ashish (at) pluGGd.in [+91 98452 06443]
Seems like they are into a very good niche which will solve a major global health problem.(Hospital based MRSA infections). A country like India loses huge number of ‘otherwise healthy’ patients just due to this problem.
Heartening to see Indian bio-companies stepping into such basic r&D to come up with innovative biotech therapeutics. Though, I wonder how much time it would take to clear DCGI regulatory approval for Phage based therapeutics in India.